(Q46902529)

English

Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia

scientific article published in January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Andreas Hochhaus

9

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

author name string

Verbeek W

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

König H

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Boehm J

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Kohl D

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Lange C

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Heuer T

6

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Scheibenbogen C

7

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Reis HE

8

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Graeven U

10

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

publication date

1 January 2006

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Acta Haematologica

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

115

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

1-2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

109-112

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Clinical decisions for chronic myeloid leukemia in the imatinib era.

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Quality assurance in RT-PCR-based BCR/ABL diagnostics--results of an interlaboratory test and a standardization approach.

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000089476

21 January 2018

Identifiers

10.1159/000089476

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16424660

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46902529&oldid=2137402823"